MX2019009212A - Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih). - Google Patents

Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2019009212A
MX2019009212A MX2019009212A MX2019009212A MX2019009212A MX 2019009212 A MX2019009212 A MX 2019009212A MX 2019009212 A MX2019009212 A MX 2019009212A MX 2019009212 A MX2019009212 A MX 2019009212A MX 2019009212 A MX2019009212 A MX 2019009212A
Authority
MX
Mexico
Prior art keywords
formula
atazanavir
atv
analogues
treating hiv
Prior art date
Application number
MX2019009212A
Other languages
English (en)
Spanish (es)
Inventor
O Link John
M Bacon Elizabeth
J Cottell Jeromy
Kato Darryl
Anne Katana Ashley
Alejandra Trejo Martin Teresa
Yang Zheng-Yu
Chin Elbert
Shapiro Nathan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61244746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009212(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2019009212A publication Critical patent/MX2019009212A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
MX2019009212A 2017-02-06 2018-02-05 Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih). MX2019009212A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455348P 2017-02-06 2017-02-06
PCT/US2018/016893 WO2018145021A1 (en) 2017-02-06 2018-02-05 Atazanavir (atv) analogues for treating hiv infections

Publications (1)

Publication Number Publication Date
MX2019009212A true MX2019009212A (es) 2019-09-27

Family

ID=61244746

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009212A MX2019009212A (es) 2017-02-06 2018-02-05 Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).
MX2022012616A MX2022012616A (es) 2017-02-06 2019-08-02 Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012616A MX2022012616A (es) 2017-02-06 2019-08-02 Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).

Country Status (35)

Country Link
US (5) US10294234B2 (enExample)
EP (2) EP3909949B1 (enExample)
JP (4) JP6814304B2 (enExample)
KR (4) KR102430812B1 (enExample)
CN (3) CN115991708A (enExample)
AR (1) AR110922A1 (enExample)
AU (3) AU2018215546B2 (enExample)
CA (1) CA3051588C (enExample)
CL (1) CL2019002204A1 (enExample)
CO (1) CO2019008531A2 (enExample)
CR (1) CR20190354A (enExample)
CY (1) CY1124276T1 (enExample)
DK (1) DK3577110T3 (enExample)
DO (1) DOP2019000201A (enExample)
EA (1) EA201991684A1 (enExample)
ES (1) ES2877595T3 (enExample)
HR (1) HRP20210732T1 (enExample)
HU (1) HUE054690T2 (enExample)
IL (1) IL268282B2 (enExample)
JO (1) JOP20180009A1 (enExample)
LT (1) LT3577110T (enExample)
MX (2) MX2019009212A (enExample)
MY (2) MY207716A (enExample)
NZ (1) NZ776008A (enExample)
PE (1) PE20191260A1 (enExample)
PH (1) PH12019501786A1 (enExample)
PL (1) PL3577110T3 (enExample)
PT (1) PT3577110T (enExample)
SA (1) SA519402405B1 (enExample)
SG (1) SG11201907058TA (enExample)
SI (1) SI3577110T1 (enExample)
TW (3) TWI701243B (enExample)
UA (1) UA123298C2 (enExample)
UY (1) UY37592A (enExample)
WO (1) WO2018145021A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
CA3216031A1 (en) * 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI766172B (zh) * 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US12421235B2 (en) * 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022159877A1 (en) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025212814A1 (en) 2024-04-03 2025-10-09 Gilead Sciences, Inc. Anti-hiv compounds
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2847064A1 (de) * 1978-10-28 1980-05-08 Boehringer Mannheim Gmbh Verwendung von 2-cyanaziridinen als therapeutica bei strahlenschaeden
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5753652A (en) 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
DK0521827T3 (da) 1991-07-03 1996-11-11 Ciba Geigy Ag Farmakologisk virksomme hydrazinderivater og fremgangsmåde til deres fremstilling
NZ249789A (en) 1992-03-11 1997-07-27 Narhex Ltd Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
AU2003200066B9 (en) 1992-03-11 2007-02-15 Narhex Limited Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons
AU4220493A (en) 1992-05-07 1993-11-29 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
ES2093394T3 (es) 1992-12-23 1996-12-16 Ciba Geigy Ag Derivados de hidrazina antiretrovirales.
US5461067A (en) 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
ES2177816T3 (es) 1995-11-21 2002-12-16 Novartis Ag Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas.
TW409125B (en) 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
EP0915841B1 (en) 1996-07-17 2002-02-27 Novartis AG Anilinopeptide derivatives
CH694251A5 (de) 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
EP2194038A3 (en) 1999-12-23 2010-09-01 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
JP2004534771A (ja) 2001-05-22 2004-11-18 イーラン　ファーマスーティカルズ、インコーポレイテッド アザヒドロキシル化エチルアミン化合物
MXPA03011399A (es) 2001-06-08 2004-07-01 Elan Pharm Inc Metodos para tratar la enfermedad de alzheimer.
JP2005506979A (ja) 2001-08-28 2005-03-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー オキソ置換及びヒドロキシ置換炭化水素のキナルドイル−アミン誘導体を使用するアルツハイマー病の治療方法
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005061487A1 (en) 2003-12-11 2005-07-07 Abbott Laboratories Hiv protease inhibiting compounds
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
ATE434621T1 (de) 2004-02-27 2009-07-15 Schering Corp Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
AU2005270124B2 (en) 2004-07-06 2011-09-08 Abbvie Inc. Prodrugs of HIV protease inhibitors
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
PL1851193T3 (pl) 2005-02-10 2009-09-30 Medivir Ab Inhibitory proteazy HIV
CA2667445A1 (en) 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
WO2008011116A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
NZ573887A (en) * 2006-07-21 2012-02-24 Gilead Sciences Inc Antiviral protease inhibitors
JP5000704B2 (ja) 2007-03-09 2012-08-15 パイオニア株式会社 Ａｖ編集装置、ａｖ処理装置、ａｖ編集システム、操作装置、ａｖ編集方法およびプログラム
CA2681718A1 (en) 2007-03-23 2008-10-02 University Of Massachusetts Hiv-1 protease inhibitors
CA2692028C (en) 2007-06-12 2013-06-04 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20110178305A1 (en) 2008-05-08 2011-07-21 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
TWI466735B (zh) 2008-09-18 2015-01-01 Gs Yuasa Int Ltd 紫外線照射裝置
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
US20120041019A1 (en) 2008-12-17 2012-02-16 Mutz Mitchell W Protease inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120108529A1 (en) 2009-05-15 2012-05-03 Webb Ii Robert R Protease inhibitors
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
WO2011014494A1 (en) 2009-07-29 2011-02-03 Schering Corporation ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES
EP2292589A1 (en) 2009-09-02 2011-03-09 IMTM GmbH Novel multifunctional peptidase inhibitors, especially for medical use
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
CN102190638A (zh) * 2010-03-16 2011-09-21 中国科学院上海药物研究所 联芳基醇二胺类化合物、其药物组合物、制备方法及应用
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
PH12013500011A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
JP6006211B2 (ja) 2010-09-02 2016-10-12 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ３員環の縮合エーテルカルバメートおよびその使用
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
WO2012092188A1 (en) 2010-12-27 2012-07-05 Ghosh Arun K Hydrogen bond forming p1 ligands and methods for treating hiv
WO2012092168A1 (en) 2010-12-27 2012-07-05 Purdue Research Foundation Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv
JP5918848B2 (ja) 2011-04-21 2016-05-18 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール化合物およびその薬学的使用
WO2012170792A1 (en) 2011-06-10 2012-12-13 Concert Pharmaceuticals, Inc. Atazanavir metabolite derivatives
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
US9341365B2 (en) 2012-01-12 2016-05-17 Daniel L. Gan Eversible candle holder
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (en) 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US20160002159A1 (en) * 2013-02-13 2016-01-07 Neal ZONDLO Perfluoro-tert-butyl hydroxyproline
KR20160078382A (ko) 2013-10-24 2016-07-04 브리스톨-마이어스 스큅 컴퍼니 인간 면역결핍 바이러스 복제의 억제제
WO2015097667A2 (en) 2013-12-23 2015-07-02 Cellworks Group, Inc., A composition, process of preparation of said composition, kit and a method of treating cancer
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015175704A1 (en) * 2014-05-14 2015-11-19 The Regents Of The University Of California Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
EP3142659B1 (en) 2014-05-16 2021-03-24 Purdue Research Foundation Hiv-1 protease inhibitors and uses thereof
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
AR104389A1 (es) 2015-04-23 2017-07-19 Bristol Myers Squibb Co Inhibidores de la replicación del virus de inmunodeficiencia humana
EP3294732B1 (en) 2015-05-15 2019-09-25 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
JP7042804B2 (ja) * 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds

Also Published As

Publication number Publication date
KR102749565B1 (ko) 2025-01-03
LT3577110T (lt) 2021-07-12
US20230027055A1 (en) 2023-01-26
US12084455B2 (en) 2024-09-10
AU2018215546A1 (en) 2019-08-22
CN115093421A (zh) 2022-09-23
NZ776008A (en) 2025-10-31
SI3577110T1 (sl) 2021-08-31
KR20190115458A (ko) 2019-10-11
KR20250008988A (ko) 2025-01-16
HRP20210732T1 (hr) 2021-09-17
PH12019501786A1 (en) 2020-06-29
KR102547909B1 (ko) 2023-06-28
AU2018215546B2 (en) 2020-08-13
TW201840555A (zh) 2018-11-16
BR102018002152A2 (pt) 2018-10-30
BR102018002152A8 (pt) 2022-11-16
JOP20180009A1 (ar) 2019-01-30
KR102430812B1 (ko) 2022-08-11
WO2018145021A1 (en) 2018-08-09
JP2021073287A (ja) 2021-05-13
CL2019002204A1 (es) 2019-12-20
TWI794629B (zh) 2023-03-01
US10294234B2 (en) 2019-05-21
US20180258097A1 (en) 2018-09-13
CN115991708A (zh) 2023-04-21
EA201991684A1 (ru) 2020-02-11
US10752636B2 (en) 2020-08-25
PL3577110T3 (pl) 2021-10-25
JP7282112B2 (ja) 2023-05-26
SG11201907058TA (en) 2019-08-27
CR20190354A (es) 2019-09-19
PE20191260A1 (es) 2019-09-18
MY207716A (en) 2025-03-14
JP2021046422A (ja) 2021-03-25
JP6814304B2 (ja) 2021-01-13
HUE054690T2 (hu) 2021-09-28
CN115093421B (zh) 2025-06-17
CN110536889A (zh) 2019-12-03
IL268282B2 (en) 2023-02-01
UA123298C2 (uk) 2021-03-10
TW202511265A (zh) 2025-03-16
US20190308983A1 (en) 2019-10-10
TW202344506A (zh) 2023-11-16
AU2020264300A1 (en) 2020-12-03
IL268282A (en) 2019-09-26
IL268282B (en) 2022-10-01
EP3909949A1 (en) 2021-11-17
SA519402405B1 (ar) 2024-03-03
EP3909949B1 (en) 2025-10-15
US11078208B1 (en) 2021-08-03
MX2022012616A (es) 2022-11-07
PT3577110T (pt) 2021-06-17
CY1124276T1 (el) 2022-07-22
KR20230097222A (ko) 2023-06-30
TWI854464B (zh) 2024-09-01
CA3051588C (en) 2022-08-23
JP2020506941A (ja) 2020-03-05
AU2020264300B2 (en) 2022-08-25
CN110536889B (zh) 2022-12-16
CO2019008531A2 (es) 2019-10-31
TW202043219A (zh) 2020-12-01
MY200608A (en) 2024-01-05
DK3577110T3 (da) 2021-06-14
ES2877595T3 (es) 2021-11-17
CA3051588A1 (en) 2018-08-09
EP3577110A1 (en) 2019-12-11
AR110922A1 (es) 2019-05-15
DOP2019000201A (es) 2019-08-30
JP2022172294A (ja) 2022-11-15
UY37592A (es) 2018-08-31
AU2022271510A1 (en) 2023-01-05
TWI701243B (zh) 2020-08-11
US12479853B2 (en) 2025-11-25
EP3577110B1 (en) 2021-04-21
KR20220116340A (ko) 2022-08-22
NZ755929A (en) 2021-08-27
JP7105853B2 (ja) 2022-07-25
US20250042910A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
MX2019009212A (es) Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
AR118707A1 (es) Inhibidores de la proteasa del vih
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY35362A (es) Compuestos terapéuticos
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
EA201790758A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CR20190446A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue